ANIMAL MODEL MARKET ANALYSIS

Market Challenges And Opportunities

Market Restraints:

1. Strict regulations and guidelines is expected to hamper growth of the global animal model market. For example, implementation of laws and regulations for animal protection and welfare has led to restrictive practices and restrictions on the use of animals for various purposes. Many countries worldwide have banned the usage of animal models.
2. Growing opposition on animal testing by several organizations is expected to hinder growth of the global animal model market. There are many organizations worldwide that are against animal testing. Moreover, a Pew Research Center poll found that around 52% of U.S. adults oppose the use of animal models in scientific research.

Market Drivers:

1. Rise in usage of animal models in pre-clinical development by several research laboratories and biopharmaceutical industries is expected to augment the growth of the global animal model market during the forecast period. For example, in December 2021, World Health Organization (WHO) launched the SARS-CoV-2 Omicron variant assays and animal models study tracker, even as the highly mutant variant is spreading fast across the globe. WHO is already conducting research studies on variants of the SARS-CoV2 virus.
2. Increasing implications of mouse clinical trials for more predictive outcomes is expected to boost the growth of the global animal model market during the forecast period. For example, in January 2020, Taconic Biosciences (Taconic Farms, Inc.), a global leader in providing drug discovery animal model solutions, expanded its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.

Market Opportunities:

1. The outbreak of COVID-19 is expected to offer significant growth opportunities for players in the global animal model market. For instance, in April 2021, Taconic Biosciences announced the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit. hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.
2. Increasing number of research and development activities are expected to provide lucrative growth opportunities for players in the global animal model market. For instance, according to the WHO, between 1999 and 2021, the U.S. had the highest total number of trials (157,618), followed by China (80,333) and Japan (57,754). Moreover, in 2021, the U.S. and Germany led R&D (research and development) funding followed by a high-income country for COVID-19 vaccine related research activities.